SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

The Fundrise Innovation Fund ($VCX) is seeing intense volatility and speculative interest following its recent market debut, with the community actively debating whether it is a legitimate vehicle for private equity exposure or a highly overvalued pump-and-dump scheme. Investors are fixated on the fund's heavy concentration in high-profile pre-IPO tech firms like Anthropic and SpaceX, while many remain frustrated by a six-month lock-up period that limits liquidity for early participants.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is facing significant downward pressure and intense community debate surrounding regulatory risks, Medicare reimbursement uncertainty, and potential balance sheet strain. While some investors see a long-term value opportunity at current levels, others are expressing concern over the company's technical weakness and its ability to navigate a challenging macroeconomic and political landscape.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph is capturing significant community attention as investors debate its role as critical web3 infrastructure versus concerns over token supply dilution, while recent protocol upgrades like the integration of Anthropic's Model Context Protocol continue to drive technical interest. While some traders view the current price as an undervalued accumulation opportunity for the long term, others remain skeptical, focusing on historical price volatility and questioning whether the project can reclaim its prior highs.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

The SPERMWHALE meme coin is generating significant buzz as traders debate whether it could replicate the explosive momentum seen in similar speculative crypto assets. While some investors focus on signs of accumulation and relative price stability, others remain skeptical, warning of the risks inherent in such volatile market activity.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending following the announcement of a full notice to proceed on a $2.4 billion contract to provide natural gas-fired power generation for AI data centers, a development the community views as a major valuation catalyst. Investors are actively discussing the company's long-term growth potential in the AI infrastructure space and its strategic relationship with Applied Digital, while debating whether the stock's recent volatility is due to institutional accumulation or ongoing short-seller manipulation.

FUST (Fusion token) is the companion token of FUSD - with tokenomics which mirror those of a typical cryptocurrency. FUST can be placed in the FUST Fusion Miner and used to mine free FUSD. FUST has tokenomics which mirror those of a typical cryptocurrency, and allows those Degens who buy into the FUSD philosophy - but who also enjoy the thrill of chasing fast green candles - to make their play within the structure of the FUSD ecosystem and benefit from the best of both worlds; the possibility of a fast ride upwards whilst earning a passive income paid in our appreciating stable token courtesy of their FUST bag.

FUST Token

The FUST community is buzzing over its unique ecosystem, which focuses on generating passive income through an appreciating stablecoin, FUSD, rather than relying solely on speculative price action. Investors are actively discussing the platform's yield-generating model and rumored upcoming distribution events as key drivers for potential long-term momentum.

The Estée Lauder Companies, Inc. engages in the manufacture of skin care, makeup, fragrance and hair care products. It sells products under Estée Lauder, Clinique, Origins, MAC, Bobbi Brown, La Mer, Jo Malone London, Aveda and Too Faced. The company was founded by Estee Lauder and Joseph Lauder in 1946 and is headquartered in New York, NY.

Estee Lauder Cos., Inc. - Ordinary Shares - Class A

Estee Lauder Cos. Inc

Estee Lauder is at the center of investor focus following reports that it is in merger discussions with Spanish beauty group Puig. While the market is reacting to potential dilution risks and broader concerns over debt, the community is actively debating the deal's strategic viability versus its potential downside, with some seeing a long-term turnaround opportunity.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is attracting investor interest following recent insider buying from CEO Seth Lederman and positive developments in the commercial launch of their fibromyalgia treatment, TONMYA. While shareholders remain focused on the potential for future institutional growth and strategic partnerships, community discussions are currently centered on navigating ongoing volatility, monitoring weekly prescription trends, and evaluating the company's long-term cash runway.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending due to persistent M&A speculation, with investors closely watching reports of a potential multibillion-dollar buyout by major pharmaceutical players like Eli Lilly and AstraZeneca. The community is actively discussing the stock's significant valuation premium, the impact of recent clinical data and analyst target increases, and the implications of potential government regulatory scrutiny in France.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is trending as investors debate the sustainability of its massive premium to Net Asset Value, with many comparing it to other proxy plays for high-profile private companies like SpaceX and OpenAI. While some in the community see it as a volatile vehicle to capture private unicorn growth, others express caution, highlighting that its market price significantly exceeds the reported value of its underlying holdings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts See an 86.45% Upside in Biodesix (BDSX): Can the Stock Really Move This High?

The mean of analysts' price targets for Biodesix (BDSX) points to an 86.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?

Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.

Biodesix Details Lung Test Momentum, 81% Gross Margin and Growth Plan at Barclays Conference

Biodesix (NASDAQ:BDSX) is focused on developing diagnostic tests intended to improve patient outcomes by answering specific clinical questions, Chief Financial Officer Robin Cowie said at a Barclays...

Here's Why Investors Continue to Hold Pediatrix Medical Stock

Favorable payer mix, higher neonatology acuity and prudent acquisitions will support MD's growth, while shares look undervalued versus industry peers.

Biodesix Details Lung Nodule Growth Plan, Primary Care Push at TD Cowen Healthcare Conference

Biodesix (NASDAQ:BDSX) outlined its current commercial focus, growth priorities, and financial milestones during a presentation at the 46th annual TD Cowen Healthcare Conference, where Chief...

Wall Street Analysts Think Biodesix (BDSX) Could Surge 111.62%: Read This Before Placing a Bet

The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Are Medical Stocks Lagging  Biodesix (BDSX) This Year?

Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.

Monashee Investment Management LLC Cuts Holdings in Biodesix, Inc. $BDSX

Monashee Investment Management LLC lowered its position in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 95.0% during the third quarter, according to its most recent disclosure with the Securities...

Biodesix (NASDAQ:BDSX) Announces Quarterly Earnings Results, Beats Estimates By $0.56 EPS

Biodesix (NASDAQ:BDSX - Get Free Report) released its earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by...

GSA Capital Partners LLP Has $365,000 Stake in Biodesix, Inc. $BDSX

GSA Capital Partners LLP reduced its position in Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 94.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The...

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Current Price	$14.69
Prev Close	$14.88
Open	$14.74
Dividend Yield	0.00%
50-Day Moving Average	$12.58
Beta	0.47
Avg. Volume	136,529.04
PE Ratio	-3.14

52-Week High	$20.21
52-Week Low	$3.44
Market Capitalization	$146.64M
EPS (Annual)	-$4.67
Price to Book	-49.80
Revenue Per Employee	$264,967.07

BDSX
Biodesix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BDSX News

BDSXBiodesix Inc